GAMMA Investing LLC Invests $31,000 in Arcus Biosciences, Inc. (NYSE:RCUS)

GAMMA Investing LLC acquired a new stake in Arcus Biosciences, Inc. (NYSE:RCUS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,601 shares of the company’s stock, valued at approximately $31,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RCUS. FMR LLC boosted its position in shares of Arcus Biosciences by 4.9% during the 3rd quarter. FMR LLC now owns 4,780,052 shares of the company’s stock worth $85,802,000 after purchasing an additional 222,280 shares during the period. Vanguard Group Inc. lifted its stake in Arcus Biosciences by 1.4% during the third quarter. Vanguard Group Inc. now owns 4,493,818 shares of the company’s stock worth $80,664,000 after purchasing an additional 61,040 shares in the last quarter. Barclays PLC boosted its position in shares of Arcus Biosciences by 183.4% during the third quarter. Barclays PLC now owns 470,776 shares of the company’s stock worth $8,451,000 after buying an additional 304,683 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Arcus Biosciences by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 460,841 shares of the company’s stock valued at $8,272,000 after buying an additional 24,100 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Arcus Biosciences by 3.0% in the 3rd quarter. American Century Companies Inc. now owns 457,695 shares of the company’s stock valued at $8,216,000 after buying an additional 13,373 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Stock Up 1.3 %

Shares of Arcus Biosciences stock opened at $15.70 on Monday. Arcus Biosciences, Inc. has a 52-week low of $12.95 and a 52-week high of $25.47. The company has a 50 day moving average of $17.25 and a 200 day moving average of $16.59. The company has a market capitalization of $1.43 billion, a P/E ratio of -3.78 and a beta of 0.91.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Wednesday, February 21st. The company reported ($1.08) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.01. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The firm had revenue of $31.00 million during the quarter, compared to the consensus estimate of $28.30 million. During the same quarter in the previous year, the firm posted ($0.93) earnings per share. The company’s revenue was down 8.8% compared to the same quarter last year. As a group, research analysts anticipate that Arcus Biosciences, Inc. will post -3.59 earnings per share for the current fiscal year.

Insider Activity

In related news, President Juan C. Jaen sold 3,900 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.06, for a total transaction of $78,234.00. Following the completion of the sale, the president now owns 1,211,365 shares in the company, valued at $24,299,981.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Arcus Biosciences news, COO Jennifer Jarrett sold 11,551 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total value of $202,720.05. Following the completion of the transaction, the chief operating officer now owns 215,253 shares in the company, valued at $3,777,690.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Juan C. Jaen sold 3,900 shares of Arcus Biosciences stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $20.06, for a total value of $78,234.00. Following the sale, the president now owns 1,211,365 shares in the company, valued at approximately $24,299,981.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,455 shares of company stock worth $1,014,779. 13.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RCUS. Wedbush restated an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a report on Thursday, February 22nd. Mizuho lowered their price objective on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, January 30th. Finally, Truist Financial reaffirmed a “buy” rating and set a $50.00 target price on shares of Arcus Biosciences in a research note on Monday, March 25th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.25.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.